webinar register page

Webinar banner
BioTech - Chronic/Autoimmune Disorders and Vaccines
Given that many chronic diseases have an infectious origin, what learnings can be had by the most recent innovations in vaccine development technology in raising the bar on innovations to address the huge unmet need against conditions that kill millions?

Oct 25, 2022 01:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information


Amgen Inc.
Arjen Lemmen
Vice President of Corporate Development & Strategy @Argenx Pharmaceuticals
Arjen Lemmen serves as Vice President of Corporate Development & Strategy at argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Since joining argenx in 2016, Arjen has held numerous leadership roles with perview over portfolio management, strategic dealmaking and long-term partnership building to serve the company’s severe autoimmune disease focus and expertise. He has designed and executed numerous transactions within the company’s unique discovery engine, the Immunology Innovation Program (IIP), as well as engineered strategic collaborations with companies such as AbbVie, Medison Pharma, Janssen, and most recently with Zai Lab to develop and commercialize VYVGART, argenx’s lead asset and the first and only neonatal Fc receptor (FcRn) blocker approved by the FDA, together in Greater China.
Theresa Podrebarac, MD, MSc
Senior Vice President, Clinical Development @Horizon Therapeutics
Theresa Podrebarac, M.D., M.Sc., is a physician scientist with extensive development expertise in the biotech industry. At Horizon Therapeutics, Dr. Podrebarac leads the clinical development function dedicated to bringing medicines for rare, autoimmune and severe inflammatory diseases to patients. Prior to Horizon, Dr. Podrebarac served as chief medical officer at two biotech companies focusing on rare diseases. She was also vice president, immunology clinical development at AbbVie where she helped develop approved therapies for psoriasis and rheumatoid arthritis. At Biogen, she championed the development of tools and techniques for early clinical proof of concept in diseases including scleroderma and lupus skin disease. Dr. Podrebarac holds a master of science in immunology from the University of Ottawa and a medical doctorate degree from Western University. She completed a postdoctoral fellowship in immunology at Harvard University.
Merck & Co.
Pfizer Inc.
Regeneron Pharmaceuticals - Dupixent
Regeneron Pharmaceuticals - Inmazeb
Jeff Baxter
President and CEO @VBI Vaccines, Inc.
Mr. Baxter joined VBI in September of 2009. Previously, he was a managing partner for the venture capital firm, The Column Group. Until July of 2006, Mr. Baxter was SVP, R&D Finance and Operations, of GlaxoSmithKline (GSK). In his 19 years of pharma experience, he has held line management roles in commercial, manufacturing and IT and the office of the CEO. His most recent position in R&D included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne (GSK’s in-house $125m venture capital fund). He also chaired GSK’s R&D Operating Board. Prior to GSK, he worked at Unilever. Mr. Baxter was educated at Thames Valley University and is a Fellow of the Chartered Institute of Management Accountants (FCMA).
Jaya L. Tiwari
Vice President Clinical & Regulatory Affairs USA @XVIVO Perfusion
With over 15 years’ experience in clinical research, Jaya started in the field of organ transplantation as a Pulmonary & Intensive Care Translational Outcomes Research Scholar at Columbia University. There she was a member of the research team who performed among the first successful ex-vivo lung perfusion (EVLP) procedures in the United States clinical trial using XVIVO’s XPS™ with STEEN Solution™. She was later recruited to the University of Pennsylvania to help start an EVLP program and manage organ transplant research studies on which she co-authored publications. Jaya joined XVIVO in 2015 to oversee their PreMarket Approval (PMA) EVLP trial, with XVIVO winning the first FDA approval of its kind for a lung perfusion device. Jaya was appointed to XVIVO’s senior management team in 2021 in the role of VP Clinical & Regulatory Affairs USA, where she continues to uphold XVIVO’s vision that nobody should die waiting for an organ.
Alexandra Moens
Director, Product Marketing @H1
Alexandra Moens is a PharmD who has been part of the clinical industry for over 6 years. Her aim is to make a positive impact on patient lives by working with innovative solutions, implementing enhanced clinical strategies and increasing diversity and equity in the drug development lifecycle. Her scientific background and experience working with pharmaceutical partners hand-in-hand have positively impacted clinical teams to get new insights to successfully manage their portfolio strategy in the fast evolving clinical industry.